Showing results (151-160 of 376) with videos related to

Sort By:
Pageof 38
Comptes Rendus Des Seances De L'Academie Des Sciences. Serie III, Sciences De La Vie|February 15, 1982
[In vitro modification of the morphology and the growth of cells infected with scrapie (author's transl)]P Markovits, D Dormont, R Maunoury, et al.
Targeted Oncology|April 24, 2013
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06C Villanueva, G Romieu, J Salvat, et al.
Journal of Neuroradiology = Journal De Neuroradiologie|March 31, 2005
Acute demyelination: an insight into the effect of mitoxantrone on CNS lesionsA Tourbah, J L Stievenart, G Edan, et al.
AIDS Research and Human Retroviruses|January 1, 1996
Inhibition of human immunodeficiency virus infection by heparin derivativesP Clayette, E Moczar, A Mabondzo, et al.
Journal of Neuroradiology = Journal De Neuroradiologie|July 27, 2013
Imaging findings of intraventricular and ependymal lesionsL Vandesteen, A Drier, D Galanaud, et al.
Bulletin Du Cancer|July 1, 1993
[Treatment with cytokines of metastatic kidney cancer: the Lyon experience]S Négrier, A Mercatello, B Coronel, et al.
British Journal of Cancer|November 1, 1993
Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patientsT Philip, S Negrier, C Lasset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycinY Merrouche, S Negrier, C Bain, et al.
Bone Marrow Transplantation|October 1, 1991
Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot studyS Negrier, J Y Ranchere, I Philip, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumorsG Catimel, R Coquard, J P Guastalla, et al.
Pageof 38